Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

68 trials

NCT07902817
Recruiting
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Phase 3 · United States · 4 sites
Registry update: 3 Nov 2026
NCT07773727
Recruiting
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Phase 2 · Belgium, Czechia, Spain, Italy, Japan, Poland, United States · 29 sites
Registry update: 27 Oct 2026
NCT07822100
Recruiting
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Not applicable · China · 1 site
Registry update: 16 Sept 2026
2024-519638-22-00
Recruiting
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
Phase 3 · Belgium, Czechia, Germany, Spain, France, Greece, Croatia, Italy · 33 sites
Registry update: 30 Oct 2026
NCT07498335
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Phase 3 · China, Colombia, Spain, France, Japan, South Korea, Taiwan, United States · 22 sites
Registry update: 6 Nov 2026
NCT07606352
Recruiting
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Phase 2 · Australia · 8 sites
Registry update: 17 Sept 2026
NCT06419205
Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Phase 2 · Brazil, United States · 4 sites
Registry update: 1 Oct 2026
NCT07582133
Recruiting
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Phase 2 · China · 1 site
Registry update: 22 Jul 2026
NCT07604311
Recruiting
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
Phase 4 · China · 1 site
Registry update: 2 Sept 2026
NCT07522099
Recruiting
Chinese Adults With Kidney Disease
Phase 2 · China · 9 sites
Registry update: 3 Sept 2026
NCT07614477
Recruiting
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Phase 2 · China · 2 sites
Registry update: 5 Aug 2026
NCT07541287
Recruiting
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Phase 2 · Australia, South Korea, New Zealand, Taiwan, United States · 20 sites
Registry update: 30 Oct 2026
NCT07586267
Recruiting
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Early phase 1 · China · 1 site
Registry update: 14 May 2026
NCT07498673
Recruiting
A Study of YKST02 in Participants With Primary IgA Nephropathy
Early phase 1 · China · 1 site
Registry update: 12 May 2026
NCT07390123
Recruiting
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Phase 3 · China · 9 sites
Registry update: 28 May 2026
NCT07507201
Recruiting
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Early phase 1 · China · 1 site
Registry update: 2 Apr 2026
NCT07182227
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
Phase 1/2 · United Kingdom, United States · 10 sites
Registry update: 9 Sept 2026
NCT07146906
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Phase 2 · Brazil, China, Czechia, Germany, Spain, Italy, Japan, South Korea, Poland, Taiwan, United States · 30 sites
Registry update: 21 Oct 2026
NCT07354932
Recruiting
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Phase 2 · China · 2 sites
Registry update: 13 May 2026
NCT07375758
Recruiting
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Phase 1/2 · China · 1 site
Registry update: 13 Apr 2026

Ordered by registry start date. Freshness and sponsorship never change the order.